**Regulatory Submissions Portal Project Update Report**

**Company:** Novum Pharmaceuticals Inc.

**Quarterly Period:** April 1, 2024 - June 30, 2024 (Q2 2024)

**Executive Summary:**

The Regulatory Submissions Portal project for Novum Pharmaceuticals Inc. is currently in the Implementation phase, with Q2 2024 marking a significant milestone in its progress. The project team has made substantial strides in developing the portal's core functionality, and we are on track to meet our overall objectives. However, there have been some challenges that require attention, particularly related to training and vendor collaboration.

**Key Milestones Achieved:**

1. **Portal Development:** 70% completion rate (up from 40% Q1 2024)
The development team has successfully implemented the portal's core features, including data import, submission processing, and regulatory compliance checks.
2. **Integration with Existing Systems:** 50% completion rate (up from 20% Q1 2024)
We have made significant progress in integrating the portal with our existing systems, including our electronic health record (EHR) system and clinical trial management software.
3. **User Acceptance Testing (UAT):** Completed successfully
The UAT phase was completed without major issues, and we received positive feedback from stakeholders on the portal's usability and functionality.

**Impact on Company Goals:**

The successful completion of these milestones has positively impacted our company goals in several ways:

1. **Improved Regulatory Compliance:** The portal will enable us to streamline our regulatory submissions process, reducing the risk of non-compliance and associated penalties.
2. **Enhanced Patient Experience:** The portal's user-friendly interface and real-time data access will improve patient engagement and outcomes.
3. **Increased Efficiency:** The automated submission processing and integration with existing systems will reduce manual errors and increase productivity.

**Current Risks and Blockers:**

1. **Insufficient Training:** Some team members require additional training to effectively utilize the portal's features, particularly those related to regulatory compliance and data analysis.
2. **Vendor Collaboration Challenges:** We are experiencing some difficulties in coordinating with our vendors, including delays in software delivery and technical support issues.

To address these challenges, we have:

1. Provided additional training sessions for the development team and stakeholders.
2. Established a dedicated vendor liaison to ensure smoother communication and issue resolution.

**Next Quarter Objectives:**

1. **Portal Testing:** Complete thorough testing of the portal's functionality, including edge cases and error scenarios.
2. **User Documentation:** Develop comprehensive user documentation, including guides, tutorials, and FAQs.
3. **Regulatory Compliance Review:** Conduct a thorough review of our regulatory compliance processes to ensure alignment with industry standards.

**Deliverables and Timelines:**

1. Portal testing: Complete by August 15, 2024
2. User documentation: Complete by September 30, 2024
3. Regulatory compliance review: Complete by October 31, 2024

**Resource and Budget Overview:**

We have allocated a total budget of $5 million for the project, with the following breakdown:

1. Personnel: $2.5 million (50% of total budget)
2. Software and Hardware: $1.2 million (24% of total budget)
3. Vendor Collaboration: $800,000 (16% of total budget)
4. Miscellaneous (training, travel, etc.): $500,000 (10% of total budget)

We have a team of 15 personnel dedicated to the project, including developers, quality assurance engineers, and project managers.

In conclusion, Novum Pharmaceuticals Inc. is making steady progress on the Regulatory Submissions Portal project, with several key milestones achieved in Q2 2024. While there are some challenges that require attention, we are confident that our team can overcome these obstacles and deliver a high-quality solution that meets our company's objectives.